Sarepta Therapeutics Inc. (SRPT)
Sarepta Therapeutics Statistics
Share Statistics
Sarepta Therapeutics has 97.03M shares outstanding. The number of shares has increased by 2.65% in one year.
| Shares Outstanding | 97.03M |
| Shares Change (YoY) | 2.65% |
| Shares Change (QoQ) | 1.58% |
| Owned by Institutions (%) | 93.57% |
| Shares Floating | 92.29M |
| Failed to Deliver (FTD) Shares | 7.13K |
| FTD / Avg. Volume | 0.36% |
Short Selling Information
The latest short interest is 6.62M, so 6.93% of the outstanding shares have been sold short.
| Short Interest | 6.62M |
| Short % of Shares Out | 6.93% |
| Short % of Float | 7.25% |
| Short Ratio (days to cover) | 1.9 |
Valuation Ratios
The PE ratio is 49.14 and the forward PE ratio is 4.74. Sarepta Therapeutics's PEG ratio is -0.34.
| PE Ratio | 49.14 |
| Forward PE | 4.74 |
| PS Ratio | 6.08 |
| Forward PS | 1.5 |
| PB Ratio | 7.57 |
| P/FCF Ratio | -33.73 |
| PEG Ratio | -0.34 |
Enterprise Valuation
Sarepta Therapeutics has an Enterprise Value (EV) of 11.79B.
| EV / Sales | 6.2 |
| EV / EBITDA | 37.2 |
| EV / EBIT | -57.28 |
| EV / FCF | -34.39 |
Financial Position
The company has a current ratio of 4.2, with a Debt / Equity ratio of 0.87.
| Current Ratio | 4.2 |
| Quick Ratio | 3.18 |
| Debt / Equity | 0.87 |
| Debt / EBITDA | 4.2 |
| Debt / FCF | -3.88 |
| Interest Coverage | 11.86 |
Financial Efficiency
Return on Equity is 15.4% and Return on Invested Capital is 6.09%.
| Return on Equity | 15.4% |
| Return on Assets | 5.94% |
| Return on Invested Capital | 6.09% |
| Revenue Per Employee | $1.39M |
| Profits Per Employee | $171.46K |
| Employee Count | 1,372 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 0.43 |
Taxes
| Income Tax | 25.54M |
| Effective Tax Rate | 9.79% |
Stock Price Statistics
The stock price has increased by -52.31% in the last 52 weeks. The beta is 0.92, so Sarepta Therapeutics's price volatility has been higher than the market average.
| Beta | 0.92 |
| 52-Week Price Change | -52.31% |
| 50-Day Moving Average | 77.84 |
| 200-Day Moving Average | 114.15 |
| Relative Strength Index (RSI) | 46.94 |
| Average Volume (20 Days) | 1.97M |
Income Statement
In the last 12 months, Sarepta Therapeutics had revenue of 1.9B and earned 235.24M in profits. Earnings per share was 2.47.
| Revenue | 1.9B |
| Gross Profit | 1.58B |
| Operating Income | 218.08M |
| Net Income | 235.24M |
| EBITDA | 316.89M |
| EBIT | 279.17M |
| Earnings Per Share (EPS) | 2.47 |
Balance Sheet
The company has 1.1B in cash and 1.33B in debt, giving a net cash position of -226.59M.
| Cash & Cash Equivalents | 1.1B |
| Total Debt | 1.33B |
| Net Cash | -226.59M |
| Retained Earnings | -4.21B |
| Total Assets | 3.96B |
| Working Capital | 2.34B |
Cash Flow
In the last 12 months, operating cash flow was -205.79M and capital expenditures -136.96M, giving a free cash flow of -342.74M.
| Operating Cash Flow | -205.79M |
| Capital Expenditures | -136.96M |
| Free Cash Flow | -342.74M |
| FCF Per Share | -3.6 |
Margins
Gross margin is 83.22%, with operating and profit margins of 11.47% and 12.37%.
| Gross Margin | 83.22% |
| Operating Margin | 11.47% |
| Pretax Margin | 13.71% |
| Profit Margin | 12.37% |
| EBITDA Margin | 16.66% |
| EBIT Margin | 11.47% |
| FCF Margin | -18.02% |
Dividends & Yields
SRPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 2.03% |
| FCF Yield | -2.96% |
Analyst Forecast
The average price target for SRPT is $167.5, which is 168.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $167.5 |
| Price Target Difference | 168.3% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
Stock Splits
The last stock split was on Jul 12, 2012. It was a backward split with a ratio of 1:6.
| Last Split Date | Jul 12, 2012 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | 1.39 |
| Piotroski F-Score | 4 |